Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01759446 · ClinicalTrials.gov registry record · Phase 2
Abuse Potential of Intranasal VYCAVERT Tablets (Hydrocodone Bitartrate/Acetaminophen) in Recreational Opioid Users
A Phase 2 study of Opioid-Related Disorders, sponsored by Acura Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 44
- Enrollment target
- 1
- Study location
NCT01759446 is a Phase 2 study of Opioid-Related Disorders that has completed, run by Acura Pharmaceuticals. The registered enrollment target is 44 participants, below the 346-participant average among 47 other Opioid-Related Disorders trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01759446, a Phase 2 study of Opioid-Related Disorders, has completed, sponsored by Acura Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 44 participants
- Enrollment target
- 1
- Study location
Study Summary
To determine the relative abuse potential of VYCAVERT (hydrocodone bitartrate and acetaminophen) compared to GENERIC H/A (hydrocodone bitartrate and acetaminophen) when crushed and administered intranasally to non dependent, recreational opioid users.
Conditions Studied
Interventions
- DRUG Placebo taken first
- DRUG Generic H/A taken first
- DRUG Vycavert taken first
- DRUG Generic H/A plus i taken first
- DRUG Generic H/A plus p taken first
Study Locations (1)
Utah
- Lifetree Clinical Research - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2013-02 |
| Est. Completion | 2013-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01759446
The ClinicalTrials.gov registry entry for NCT01759446 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 346-participant average among 47 other Opioid-Related Disorders trials with a reported enrollment target (87% lower). The listed sponsor is Acura Pharmaceuticals, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Opioid-Related Disorders appearing as the primary indexed condition, and to 5 interventions - of which Placebo taken first is the first listed.
NCT01759446 reports 1 study location spanning 1 distinct geographic area - top geographies include Utah.
Frequently Asked Questions
What is clinical trial NCT01759446 about?
NCT01759446 is a clinical study titled "Abuse Potential of Intranasal VYCAVERT Tablets (Hydrocodone Bitartrate/Acetaminophen) in Recreational Opioid Users". To determine the relative abuse potential of VYCAVERT (hydrocodone bitartrate and acetaminophen) compared to GENERIC H/A (hydrocodone bitartrate and acetaminophen) when crushed and administered intranasally to non dependent, recreational opioid users.
What is the current status of trial NCT01759446?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 44 participants. The study started on 2013-02. Estimated completion is 2013-04.
What conditions does trial NCT01759446 study?
This clinical trial studies the following conditions: Opioid-Related Disorders.
What interventions are being tested in trial NCT01759446?
The interventions under investigation include: Placebo taken first (DRUG), Generic H/A taken first (DRUG), Vycavert taken first (DRUG), Generic H/A plus i taken first (DRUG), Generic H/A plus p taken first (DRUG).
Who is sponsoring clinical trial NCT01759446?
This trial is sponsored by Acura Pharmaceuticals, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01759446 being conducted?
This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Opioid-Related Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Psilocybin in Cancer Pain Study
RECRUITING · Phase 2
-
Neurocognitive Mechanisms Underlying Smartphone-Assisted Prevention of Relapse in Opioid Use Disorder
RECRUITING · Phase 2
-
Alternate-Day Buprenorphine Administration. Phase VII - 8
COMPLETED · Phase 2
-
Alternate Day Buprenorphine Administration, Phase IX - 14
COMPLETED · Phase 2
-
Methylnaltrexone for Opioid-induced Constipation in Cancer Patients
COMPLETED · Phase 2
-
Treatment of Opioid/Heroin Dependence: Comparison of Three Medication Dosing Regimens
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.